Initiating or switching to insulin degludec/insulin aspart in a real‐world population of adults with type 2 diabetes in <scp>Australia</scp>: results from a prospective, non‐interventional study
Initiating or switching to IDegAsp in a real-world population of people with T2D in Australia was associated with significant improvements in glycaemic control and body weight, and numerically lower levels of hypoglycaemia compared with baseline.
Authors
- Roland W. McCallum (ORCID: https://orcid.org/0000-0003-3574-4379)
- Robert G. Moses (ORCID: https://orcid.org/0000-0003-4177-9105)
- Gregory Fulcher (ORCID: https://orcid.org/0000-0001-8782-0420)
- Sarah J. Glastras (ORCID: https://orcid.org/0000-0002-9317-1348)
- Anthony I. Roberts (ORCID: https://orcid.org/0000-0002-2165-1246)
- Neale Cohen (ORCID: https://orcid.org/0000-0002-4441-9511)
- Michael C dʼEmden (ORCID: https://orcid.org/0000-0002-0149-639X)
- Peak Mann Mah
- Ken Y. Thong
- Katherine Davies
Institutions
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- Baker Heart and Diabetes Institute (AU)
- Royal Brisbane and Women's Hospital (AU)
- Diabetes Australia (AU)
- Royal North Shore Hospital (AU)
- Lyell McEwin Hospital (AU)
- Royal Hobart Hospital (AU)
- Illawarra Shoalhaven Local Health District (AU)
- Novo Nordisk (United States) (US)
- Northern Sydney Local Health District (AU)
- Advanced Medical Institute (Australia) (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2024-08-22
- DOI
- https://doi.org/10.1111/imj.16492
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- University of Sydney
- Novo Nordisk